Myocardial Infarction
📧 Sign up to get email alerts when something new happens for Myocardial Infarction.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2016-03-16Clinical Trial Update: Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock [Phase 2]
A Phase 2 clinical trial evaluating cyclosporine in acute myocardial infarction complicated by cardiogenic shock has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-12-07Clinical Trial Update: Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction [NA]
A clinical trial evaluating acetaminophen to prevent ischemic oxidative reperfusion injury during PCI for acute myocardial infarction was wi…
-
CLINICAL_TRIALS withdrawal · 2015-12-04Clinical Trial Update: TandemHeart to Reduce Infarct Size (TRIS Trial) [NA]
The TRIS Trial evaluating TandemHeart to reduce infarct size in acute myocardial infarction has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-11-25Clinical Trial Update: Biomarkers for Postoperative Myocardial Infarction in Cardiac Surgery.
A clinical trial investigating biomarkers for postoperative myocardial infarction after cardiac surgery has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-07-21Clinical Trial Update: Evaluation of Serial Troponin and Cardiac Multimarkers at the Point of Care in the Emergency Department
A clinical trial evaluating serial troponin and cardiac multimarkers at the point of care in the emergency department has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2015-07-10EMA Withdrawn: Clopidogrel DURA (clopidogrel (as hydrochloride)) — Mylan dura GmbH
The EMA has withdrawn Clopidogrel DURA (clopidogrel hydrochloride) from the market for peripheral vascular diseases, stroke, and myocardial …
-
CLINICAL_TRIALS withdrawal · 2015-07-03Clinical Trial Update: Inflammation in Type 2 Myocardial Infarction
This clinical trial investigating inflammation in Type 2 myocardial infarction has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-06-16Clinical Trial Update: Protective Effect of Coronary Collaterals on Infarct Size in Patients With Acute Myocardial Infarction
A clinical trial investigating the protective effect of coronary collaterals on infarct size in patients with acute myocardial infarction ha…
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment. [Phase 4]
The Phase 4 trial evaluating repeated loading dose and high-dose clopidogrel in patients with acute myocardial infarction undergoing interve…
-
CLINICAL_TRIALS withdrawal · 2015-03-03Clinical Trial Update: Clinical Registry on Sudden Death Primary Prevention at Latin America
A clinical trial registry update indicates the Sudden Death Primary Prevention study in Latin America (NCT01422174) has been withdrawn, spon…
-
EMA withdrawal · 2015-02-03EMA Withdrawn: Clopidogrel Teva Pharma B.V. (clopidogrel (as hydrobromide)) — Teva Pharma B.V.
The EMA withdrew clopidogrel Teva Pharma B.V. (clopidogrel as hydrobromide) from marketing.
-
EMA withdrawal · 2014-09-08EMA Withdrawn: Clopidogrel Qualimed (clopidogrel (as hydrochloride)) — Qualimed
EMA withdrew Clopidogrel Qualimed (clopidogrel hydrochloride) from the market.
-
CLINICAL_TRIALS withdrawal · 2014-06-16Clinical Trial Update: Medical Versus Surgical Management of Moderate Mitral Regurgitation Following Percutaneous Coronary Intervention [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating medical versus surgical management of moderate mitral regurgitation after percutaneous coronary interv…
-
CLINICAL_TRIALS withdrawal · 2014-06-09Clinical Trial Update: Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736) [Phase 3]
A Phase 3 trial evaluating vorapaxar for prevention of heart attack and stroke in acute coronary syndrome was terminated.
-
EMA withdrawal · 2014-05-12EMA Lapsed: Clopidogrel Teva Generics B.V. (clopidogrel (as hydrochloride)) — Teva Pharma B.V.
EMA has lapsed the marketing authorization for Clopidogrel Teva Generics B.V. (clopidogrel as hydrochloride).
-
EMA withdrawal · 2013-12-12EMA Withdrawn: Clopidogrel ratiopharm (clopidogrel) — Archie Samuel s.r.o.
Withdrawn clopidogrel product (Clopidogrel ratiopharm) listed by EMA; therapeutic areas include peripheral vascular diseases, stroke, and my…
-
CLINICAL_TRIALS withdrawal · 2013-08-13Clinical Trial Update: Safety and Efficacy on Cell-based Therapy in Patients With Recent Large Acute Myocardial Infarction [Phase 2]
A Phase 2 trial evaluating a cell-based therapy for patients with a recent large acute myocardial infarction has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2013-07-31Clinical Trial Update: Efficacy of Preoperative Electrocardiography
The trial evaluating preoperative electrocardiography has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-10-03Clinical Trial Update: Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients
The AstraZeneca-sponsored clinical trial using a Sicilian administrative data base in patients with acute coronary syndrome and acute myocar…
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Hexal (clopidogrel) — Acino Pharma GmbH
Clopidogrel Hexal (clopidogrel) has been withdrawn from the market by Acino Pharma GmbH.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma GmbH (clopidogrel) — Acino Pharma GmbH
Clopidogrel product from Acino Pharma GmbH has been withdrawn from the market.
-
EMA withdrawal · 2012-07-26EMA Withdrawn: Clopidogrel Acino Pharma (clopidogrel) — Acino Pharma GmbH
The EMA withdrew Clopidogrel Acino Pharma (clopidogrel) from use; linked to peripheral vascular diseases, stroke, and myocardial infarction …
-
EMA withdrawal · 2011-10-26EMA Withdrawn: Clopidogrel Sandoz (clopidogrel) — Acino Pharma GmbH
The EMA indicates withdrawal of Clopidogrel Sandoz (clopidogrel) by Acino Pharma GmbH.
-
CLINICAL_TRIALS withdrawal · 2010-01-28Clinical Trial Update: Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients [Phase 4]
A Phase 4 trial comparing intravenous and sublingual isosorbide dinitrate for relief of acute anginal episodes in acute coronary syndrome ha…
-
EMA withdrawal · 2010-01-26EMA Withdrawn: Clopidogrel BMS (clopidogrel (as hydrogen sulfate)) — Bristol-Myers Squibb Pharma EEIG
The EMA information indicates that the clopidogrel BMS product (clopidogrel as hydrogen sulfate) has been withdrawn from the market.